Health data and digital technologies will be essential for improving global health outcomes beyond the COVID-19 pandemic. Low- and middle-income nations, with fledgling digital health strategies and many barriers to overcome, stand to benefit the most.
Publications: Philip Stevens
April 18, 2020
With two-thirds of the world in lockdown and no clear way out of the novel coronavirus crisis, it’s increasingly obvious that biopharmaceutical innovation will play a pivotal role.
February 5, 2020
Severing the Link Between IP and Biomedical Innovation Isn’t the Answer to Global Health Care Challenges
Delinking the cost of R&D from the final prices of medicines and making governments the funders and planners of drug development would be rife with problems.
February 3, 2020
Separating the cost of biopharmaceutical research and development from the final market price of medicines would misalign incentives, raise bureaucratic costs, and limit innovation.
April 15, 2019
Seven case studies showcase how IP rights are enabling innovators in Latin America to help solve some of the greatest global health challenges.
May 9, 2017
The Trump administration’s trade strategy has largely taken aim at unfair trade practices in traditional industries. Yet, as Philip Stevens and Nigel Cory explain in The Hill, foreign actors are threatening another major component of the U.S. economy that we hear much less about: the theft of knowledge and IP in a wide variety of traditional and high-tech sectors.